ARTEMIS + Contingency Management for Depression

Recruiting in Palo Alto (17 mi)

Overseen by Adam W Carrico, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Research Team

Christina S Meade, PhD

Principal Investigator

Wake Forest University Health Sciences

Adam W Carrico, PhD

Principal Investigator

Florida International University

Eligibility Criteria

Project neuroARTEMIS is for HIV-positive individuals on antiretroviral medications who also use stimulants. It aims to help with depression and substance use by understanding how chronic stress affects brain and immune function.

Inclusion Criteria

I have been diagnosed with HIV.

I am currently taking daily HIV medication.

Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

Exclusion Criteria

I do not have a current brain infection.

I am currently experiencing severe symptoms of bipolar I or a psychotic disorder.

I am prescribed immunotherapy or drugs that affect my immune system.

Treatment Details

Interventions

• ARTEMIS (Behavioral Intervention)
• Contingency management for Antiretroviral (ARV) adherence (Behavioral Intervention)

Trial Overview The trial tests ARTEMIS, a positive affect intervention designed to reduce stimulant use and improve mood in people with HIV/AIDS. Participants will also receive contingency management for sticking to their antiretroviral regimen.

Participant Groups

Group I: Waitlist Control (WLC) Experimental Treatment 1 Intervention

Participants in the WLC arm will be offered the ARTEMIS intervention after the final (6-month) follow-up.

Group II: ARTEMIS Active Control 2 Interventions

Participants in this arm will receive the ARTEMIS intervention immediately following randomization.

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+

Dr. L. Ebony Boulware

Wake Forest University Health Sciences

Chief Medical Officer since 2022

MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health

Dr. Julie Ann Freischlag

Wake Forest University Health Sciences

Chief Executive Officer since 2020

BS from University of Illinois, MD from Rush University

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

Dr. Jeanne Marrazzo

National Institutes of Health (NIH)

Chief Medical Officer

MD from University of California, Los Angeles

Dr. Jay Bhattacharya

National Institutes of Health (NIH)

Chief Executive Officer

MD, PhD from Stanford University

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico

Florida International University

Collaborator

Trials

114

Recruited

19,400+

Andrés G. Gil

Florida International University

Chief Executive Officer

PhD in Medical Sociology from the University of Miami

Dr. Stuart Hart

Florida International University

Chief Medical Officer

MD from Harvard Medical School